TITLE:
Serum Y-Box Binding Protein 1 (YBX-1) and Interleukin 6 (IL-6) Are Associated with Metastasis in Breast Cancer Patients
AUTHORS:
Caroline K. Abd-Elaziz, Nadia A. Abd El Moneim, Shaymaa E. El Fek, Amira M. Arafat
KEYWORDS:
Breast Cancer, Metastasis, Y-Box Binding Protein 1, Interleukin-6, Biomarker
JOURNAL NAME:
Advances in Breast Cancer Research,
Vol.8 No.3,
July
15,
2019
ABSTRACT: Objectives: The aim of this study was
to assess the levels of Y-box binding protein 1 (YBX-1) and interleukin 6
(IL-6) in the sera of metastatic and non-metastatic breast cancer patients
(BC), investigate their clinicopathological significance and to analyze their
potential use as biomarkers of breast cancer metastasis. Methods: The study
included ninety subjects sub-grouped equally into metastatic BC, non-metastatic
BC and healthy volunteers. Serum YBX-1 and IL-6
were quantified using ELISA technique while CA 15-3 was quantified using IRMA kit. Clinical data were collected from patients’ records. Results: YBX-1 (p were significantly elevated in
metastatic and non-metastatic BC patients compared to healthy controls,
however, only YBX-1 (p 0.001) showed a significant difference with cancer metastasis.
Generally, YBX-1 and IL-6 were correlated with worse histological grade
and late clinical stage in breast cancer patients and they were also associated
with axillary lymph nodes involvement and positive vascular invasion in
metastatic BC patients. Serum YBX-1 and IL-6 levels were positively correlated
to each other (rs = 0.615, p Conclusions:
Serum YBX-1 and IL-6 are potential biomarkers of breast cancer patients with
significant correlation with bad clinicopathological characteristics. Serum
YBX-1 and IL-6 have superior sensitivity and specificity compared to CA15-3 and
can serve as potential follow up and prognostic markers.